SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Issuer

PURSUANT to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For the Month of October ~~June,~~ 2007

Commission File Number 0-30860

Axcan Pharma Inc.

(Exact Name of Registrant)

597, boul, Laurier, Mont-Saint-Hilaire (Quèbec), Canada J3H 6C4

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F		Form 40-F
		X

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also hereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes		No
		X

This Form 6-K consists of: Aan ~~June~~October 291, 2007 press release entitled “Axcan ~~Pharma~~Licenses ~~Completes~~Rights To ~~Redemption~~Cx401, ~~and~~An ~~Conversion~~Innovative ofBiological ~~All~~Product ~~$125~~In ~~Million~~Development ~~4.25%~~For ~~Convertible~~The ~~Subordinated~~Treatment Of Perianal ~~Notes~~Fistulas, ~~Due~~A ~~2008.~~Significant Unmet Medical Need”.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AXCAN PHARMA INC.

Date: June 29, 2007 By: /s/ Steve Gannon

Date: October 2, 2007	By:	/s/ Richard Tarte
	Name:	Richard Tarte
	Title:	Vice President, Corporate Development
		and General Counsel

Name: Steve Gannon

Title: Senior Vice President and Chief Financial Officer

Filing Compare · AXCAN PHARMA INC